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Recent evidence suggests that a subpopulation of
cancer cells, cancer stem cells (CSCs), is responsible
for tumor growth in colorectal cancer. However,
the role of CSCs in colorectal cancer metastasis
is unclear. Here, we identified a subpopulation of
CD26+ cells uniformly present in both the primary
and metastatic tumors in colorectal cancer patients
with liver metastasis. Furthermore, in patients with-
out distant metastasis at the time of presentation,
the presence of CD26+ cells in their primary tumors
predicted distant metastasis on follow-up. Isolated
CD26+ cells, but not CD26 cells, led to development
of distant metastasis when injected into the mouse
cecal wall. CD26+ cells were also associated with
enhanced invasiveness and chemoresistance. Our
findings have uncovered a critical role of CSCs in
metastatic progression of cancer. Furthermore, the
ability to predict metastasis based on analysis of
CSC subsets in the primary tumor may have impor-
tant clinical implication as a selection criterion for
adjuvant therapy.
INTRODUCTION
Colorectal cancer is the second leading cause of cancer death in
the United States, and approximately 50% of patients with colo-
rectal cancer develop synchronous or metachronous liver
metastases (Jemal et al., 2008). The 5 year survival rate of colo-
rectal cancer patients with metastatic disease is less than 10%
(Boyle and Ferlay, 2005). Understanding the biological mecha-
nism of metastasis is important for development of new treat-
ment strategies and markers predictive of metastasis (Chung,
1998).
Growing evidence suggests that human cancers are stem cell
diseases (Galli et al., 2004; Gutova et al., 2007; Lapidot et al.,
1994; Li et al., 2007; O’Brien et al., 2007; Reya et al., 2001).
Cancer cells with the properties of stem cells, known as cancer
stem cells (CSCs), possess the ability to self-renew, to undergomultilineage differentiation, and to survive adverse tissue micro-
environment (Lorusso and Ru¨egg, 2008; Mueller et al., 2009;
Tang et al., 2007). Normal stem cells are the longest lived cells
in tissues and are more likely to accumulate mutations over
time and ultimately assume a malignant phenotype. Alterna-
tively, some studies suggest that CSCs may arise from mutated
progenitor cells called transit-amplifying cells, which then
develop the capacity of unregulated self-renewal (Huntly et al.,
2004; Jamieson et al., 2004). Recent data support the existence
of CSCs in human cancers, including colorectal cancer. Thus far,
studies in colorectal cancer have identified CSCs capable of initi-
ating tumor development (Dalerba et al., 2007; O’Brien et al.,
2007; Ricci-Vitiani et al., 2007). Little is known of the role of
CSCs in metastasis of human cancers. One study showed that
a subpopulation of CSCs isolated from a metastatic pancreatic
cancer cell line was responsible for the metastatic phenotype
(Hermann et al., 2007). However, the hypothesis that a specific
subset of CSCs is responsible for tumor metastasis needs to
be proven in CSCs isolated from human cancer specimens.
Colorectal cancer is one of the few cancers for which surgical
resection of liver metastasis can prolong survival, and therefore
we were able to obtain fresh tumor tissues from both primary
colorectal cancer and synchronous or metachronous liver
metastasis. We hypothesized that there may be a subset of
CSCs capable of forming metastasis in addition to tumorigen-
esis. Initial studies have suggested CD133 as a marker of
tumor-initiating cells of colorectal cancer (O’Brien et al., 2007;
Ricci-Vitiani et al., 2007), though its role as a marker of colorectal
CSCs has been subsequently challenged (LaBarge and Bissell,
2008). CSCs in human colorectal cancer may represent a hetero-
geneous population (Botchkina et al., 2009). CD133 may not be
the only marker, but it remains the most widely reported marker
of CSCs of colorectal cancer validated by different groups
(Dallas et al., 2009; Ferrand et al., 2009; Haraguchi et al.,
2008). In this study, we further assessed the expression of two
other markers, CD44 and CD26, in colorectal cancers and inves-
tigated the role of CSC subsets expressing these markers in
tumorigenesis and metastasis. CD44 is selectively expressed
on renewing epithelial cells lining the intestinal crypts, and has
been recently identified as a major WNT signaling target. Its
strong expression in neoplastic crypts and advanced adenomas
suggests its potential role in intestinal tumorigenesis. Consistent
with this hypothesis, CD44 has recently been identified as a CSCCell Stem Cell 6, 603–615, June 4, 2010 ª2010 Elsevier Inc. 603
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CD26+ Cancer Stem Cells in Colorectal Cancermarker of colorectal cancer (Dalerba et al., 2007). CD26 is a
110 kDa cell surface glycoprotein with intrinsic dipeptidyl pepti-
dase IV(DPPIV) activity expressed on a variety of cell types
including T lymphocyte, endothelial cells, and epithelial cells,
and it is known to have multiple biological functions (Pro and
Dang, 2004; Thompson et al., 2007). Recent work suggests
that CD26 plays a significant role in tumor pathogenesis and
progression (Pro and Dang, 2004). In this study, we identified
a subpopulation of CD26+ CSCs that is not only endowed with
tumor-initiating properties, but is also capable of forming liver
metastasis.
RESULTS
Markers of Cancer-Initiating Cells in Human
Colorectal Cancer
To identify markers likely to be associated with tumorigenesis
and metastasis in colorectal cancer, a panel of 13 stem/progen-
itor cell markers were screened in 10 paired human colorectal
cancers without distant metastasis and their corresponding
normal colon tissues and in 10 liver metastases from colorectal
cancer (Table S1 available online). Only CD44 and CD133 were
differentially expressed between primary tumors and normal
colon tissues. Expression of CD44 and CD133 was similar
between primary tumors and liver metastases. Among the
markers screened, only CD26 showed differential expression
between primary tumors and metastases, being positive in all
10 metastases but in only 2 primary tumors.
We further collected tumor samples of 43 patients with primary
colorectal cancers, including 27 without metastasis on presenta-
tion and 5 with synchronous liver metastasis, and tumor samples
of 15 metachronous liver metastases (diagnosed > 6 months
after resection of primary tumor). The expression of CD133,
CD44, and CD26 in dissociated tumor cells was evaluated by
three-color flow cytometry (Figure 1). The distribution of different
cell populations characterized by these three markers in 4
representative primary tumors and 4 representative liver metas-
tases is shown in Table S2. Among the 43 primary tumors, 32
(74%) were positive for CD133. In the 5 patients with synchro-
nous liver metastasis, both the primary and metastatic tumors
were positive for CD133. The expression of CD26 and CD44
in these patients is presented in Table 1. Among the 27 patients
without liver metastasis on presentation, only 8 had CD26+
cells (CD133+CD26+CD44+ or CD133+CD26+CD44). Of the
19 tumors with CD26- cells, 14 harbored CD44+ cells (Figure 1A).
In contrast, in patients with synchronous liver metastasis, CD26
was expressed in all primary tumors and liver metastases. The
CD133+CD26+CD44+ subpopulation was present in all synchro-
nous metastatic tumors and 3 the primary tumors; the remaining
2 primary tumors had CD133+CD26+CD44 cells (Table 1, Fig-
ures 1B and 1C). Similarly, CD26+ cells were present in all
metachronous metastases (Table 1). Primary tumor specimens
available from 4 of these cases all harbored CD26+ cells (Table 1).
The different cell populations shown in Figure 1 were analyzed
after gating on CD45 to exclude hematopoietic cells. Further-
more, these cell populations were negative for stromal cell
markers CD117 and FAP (data not shown). Hence, these cell
populations were likely tumor cells rather than hematopoietic
or stromal cells.604 Cell Stem Cell 6, 603–615, June 4, 2010 ª2010 Elsevier Inc.The presence of CD26+ cells was significantly associated with
poor tumor differentiation (p = 0.013) and microscopic vascular
invasion (p = 0.001). There were trends of association between
microscopic vascular invasion (p = 0.099) or poor tumor differen-
tiation (p = 0.064) and liver metastasis. In contrast, the associa-
tion of CD26+ cells with liver metastasis was statistically signifi-
cant (p < 0.001), suggesting that CD26+ cells is an independent
marker of distant metastasis. DPPIV activity was much higher in
CD26+ cells than CD26 cells in both primary and metastatic
tumors (Figure 1D).
Among the 27 patients without distant metastasis on presen-
tation, distant metastasis was subsequently diagnosed in 5
after follow-up of 8–15 months, all with CD26+ cells in the
primary tumor (p = 0.004, Table 1). In contrast, none of the 19
patients with CD26 cells developed distant metastasis. This
finding further supports that CD26+ cells may be a predictive
marker of distant metastasis in colorectal cancer. In the other
3 patients with CD26+ cells, no distant metastasis was observed
at the time of data analysis but their follow-up was relatively
short (<8 months). All 16 synchronous or metachronous liver
metastases harbored CD26+ cells, and 7 developed further
metastasis after short follow-up of 5–7 months despite adjuvant
chemotherapy.
Tumorigenicity of CSC Subpopulations Characterized
by Different Markers
Next, we demonstrated the tumorigenic capacity of CSCs iso-
lated from tumor samples. Subcutaneous injection of as few as
1 3 103 CD133+CD26+ cells conferred tumor formation in
SCID mice. Post-sorting flow cytometry showed that the
CD133+CD26+ cells were negative for CD45, a hematopoietic
stem cell marker, and cytokeratin 20 (CK20), an intermediate fila-
ment protein restricted to differentiated cells in intestinal epithe-
lium (Figure 2A; Moll, 1998). The engraftment rate of different cell
subpopulations was then investigated. Injection of 1 3 103
purified CD133+CD26+CD44+, CD133+CD26CD44+, or CD133+
CD26+CD44 cells from a CD133+CD26+CD44+ primary tumor
all conferred tumor formation in all three, with the lowest engraft-
ment rate in CD133+CD26+CD44 cells (Table S3). CD133
CD26+CD44+, CD133CD26CD44+, or CD133CD26+CD44
cells from the same human tumor could also form tumors in
SCID mice.
To further demonstrate the different tumorigenic potential
of cells within the tumor bulk, 1 3 105 CD133+CD26+CD44+,
CD133+CD26+CD44, CD133+CD26CD44+, C133+CD26
CD44, and CD133CD26CD44 cells from five different
patients were subcutaneously injected into SCID mice to observe
difference in tumor growth rate (Figure 2B). Among the CD133+
cells, tumor growth rate was the highest with CD133+CD26+
CD44+ cells, but CD133+CD26CD44+, CD133+CD26+CD44,
and CD133+CD26CD44 cells were also tumorigenic in mice.
CD133CD26+CD44+, CD133CD26CD44+ or CD133CD26+
CD44 cells also initiated tumor growth. In contrast, injection of
as many as 5 3 105 CD33CD26CD44 cells from the same
tumor failed to induce tumor formation. Injection of 5 3 105
unsorted cells from the tumor bulk conferred tumor formation in
mice, albeit much more slowly (Figure 2B; Table S3). CD133+
CD26CD44+- and CD133+CD26+CD44+-derived tumor xeno-
grafts consistently reproduced histologically similar tumors
Figure 1. Different Subpopulations of CSCs in Primary and Metastatic Human Colorectal Cancers
(A) Three-color flow cytometry of a representative primary colorectal cancer with 3.8% of CD133+ cells. The population was gated, further analyzed for CD26 and
CD44, and was shown to express a CD133+CD26CD44+ subpopulation (3.3%, patient P10). N, normal; T, tumor.
(B) Three-color flow cytometry of a representative primary tumor from a patient with synchronous liver metastasis (patient S3) harboring a subpopulation of
CD133+CD26+CD44+ cells (8.4%). Middle panel shows the whole cell population scatter plot (left) and gating for CD45 cells (right). The percentage of cells
in different subpopulations within the tumor after gating is shown in the lower panel and summarized in the prism table on the top panel. Numbers in each table
cell refer to the percentage of cells isolated from the tumor after gating on CD45 to exclude hematopoietic cells.
(C) Three-color flow cytometry of the corresponding metastatic tumor from the patient in (B), with the middle panel showing the whole cell population scatter plot
(left) and gating for CD45 cells (right). The percentage of cells in different subpopulations within the tumor after gating is shown in the lower panel and summa-
rized in the prism table (top). Numbers in each table cell refer to the percentage of cells isolated from the tumor after gating on CD45.
(D) CD26 enzymatic activity in CD26+ and CD26 cells isolated from five primary colorectal cancers and five liver metastases with CD26+ cells, showing very low
enzymatic activity in the CD26 cells.
See also Tables S1 and S2.
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CD26+ Cancer Stem Cells in Colorectal Cancerupon serial passages (Figures 2C and 2D). In contrast, CD133
CD26CD44 cells isolated from the xenografts were not tumor-
igenic in secondary mice.
Sphere Formation of Patient-Derived CSCs
We examined the ability of the CD26+ cells to form sphere
in vitro, another property of CSCs. CD133+CD26+ cells andCD133+CD26CD44+ cells from primary and metastatic tumors
of a patient formed spheres when cultured with growth factors,
whereas CD133CD26CD44 cells did not (Figures 3A and
3B; Table S4). Moreover, cells dissociated from the spheres
could form subspheres in serial passages. CD133+CD26CD44
cells could also form subspheres in serial passages, albeit less
efficiently (Figure 3C). Subcutaneous and orthotopic injectionsCell Stem Cell 6, 603–615, June 4, 2010 ª2010 Elsevier Inc. 605
Table 1. Expression of CD44 and CD26 in CD133+ CSCs of Primary Colon Cancer and Liver Metastasis
CD133+CD26+CD44 CD133+CD26+CD44+ CD133+CD26CD44+ CD133+CD26CD44
Primary colorectal cancer without distant
metastasis (n = 27)
3 5 14 5
Dukes A: n = 6 0 0 3 3
B: n = 13 0 1 (1)a 10 2
C: n = 8 3 (2)a 4 (2)a 1 0
Tumor grade: Well differentiated 0 0 1 4
Moderately differentiated 0 1 4 3
Poorly differentiated 3 4 6 1
Presence of microscopic vascular invasion 3 4 3 0
Colorectal cancer with synchronous liver
metastasis (n = 5)
2 3 0 0
Primary tumor
Liver metastasis 0 5 [2]b 0 0
Tumor grade: Well differentiated 0 0 0 0
Moderately differentiated 0 0 0 0
Poorly differentiated 2 3 0 0
Presence of microscopic vascular invasion 1 3 0 0
Metachronous liver metastasis (n = 11) 3 [3]b 8 [2]b 0 0
Marker is defined positive when expressed in greater than 1% of total tumor cell population.
a Number in parentheses indicate number of Dukes A, B, or C patients who developed liver metastasis after resection of primary colorectal cancer
during follow-up of 8–15 months. Specimens were available in four of these five patients who developed liver metastasis. CSCs isolated from the liver
metastases were CD133+CD26+CD44 in one patient and CD133+CD26+CD44+ in the other three patients.
b Number in square brackets [ ] indicate number of patients with liver metastasis at the time of presentation who developed further liver metastasis or
other distant organ metastasis during follow-up after resection.
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SCID mice (Figures 3D and 3E).
Metastatic Capacity of CSC Subpopulations
Characterized by Different Markers
Since CD26+ cells were detected in patients with liver metastasis
from colorectal cancer, a critical question is whether this CSC
subset has metastatic capacity in addition to its tumorigenic
capacity. Indeed, orthotopic implantation of CD133+CD26+
CD44+ CSCs from the primary tumor of a patient with synchro-
nous liver metastasis into the mouse cecal wall led to tumor
growth in the colon after 5–6 weeks, and liver metastasis after
12–14 weeks (Figure 4A). Similar results were obtained with
CD133+CD26+CD44, CD133CD26+CD44+, and CD133CD26+
CD44 cells, though with lower efficiencies (Table S3). In con-
trast, tumor development of orthotopically implanted CD133+
CD26CD44+ or CD133+CD26CD44 cells from the same
patient were confined to the cecum, and CD133CD26CD44
cells did not form any tumors. Importantly, histological examina-
tion of the metastatic lesions in SCID mice showed remarkable
similarity to the original metastatic tumor from the patient
(Figure 4B). Furthermore, orthotopic implantation of CD133+
CD26+ cells from primary colorectal tumors of two patients
(one CD44+ and one CD44) without liver metastasis at the
time of resection also led to development of metastasis in
SCID mice (Figure 4C). These two patients subsequently devel-
oped distant metastasis on follow-up. Table S5 summarizes the
tumorigenic and metastatic capacities of CD26+ cells isolated
from patients with liver metastasis.606 Cell Stem Cell 6, 603–615, June 4, 2010 ª2010 Elsevier Inc.The process of distant metastasis involves invasion of tumor
cells through extracellular matrix (ECM), intravasation, extrava-
sation of the circulating tumor cells in the distant organ, and
growth into a metastasis. We detected circulating CD133+
CD26+CD44+ cells in the portal vein of mice at week 6 after cecal
wall injection, demonstrating the invasion of CD26+ cells into
the circulation (Figure 4D). In contrast, no circulating CD133+
CD26CD44+ cells were detected in mice orthotopically
implanted with CD133+CD26CD44+ cells. Next, to investigate
whether circulating CD26+ CSCs were capable of forming meta-
static growth in the liver, we performed intraportal vein injection
of CD133+CD26+CD44+ cells and CD133+CD26CD44+ cells,
respectively. Only CD133+CD26+CD44+ cells led to develop-
ment of liver metastasis (Figure 4D).
Invasiveness of CD26+ CSCs
To test whether CD26+ CSCs had enhanced invasive and migra-
tory properties as compared to CD26 CSCs, matrigel invasion
assays and transwell migration assays were performed. Both
invasion and migratory capacities of CD26+ cells were much
higher compared with CD26 cells in different patient tumors
(Figure 4E). Furthermore, as CD26 plays a role in cell adhesion
to the ECM (Sato et al., 2005), we evaluated the capacity of
CD26+ CSCs in binding to the ECM. CD26+ cells displayed
higher adhesion to fibronectin and type 1 collagen compared
with CD26 cells (Figure 4F).
Invasion of tumor cells involves the loss of cell-cell interaction
together with acquisition of migratory properties, and is often
associated with epithelial-mesenchymal transition (EMT) of cells.
Figure 2. Tumorigenic Potential of Different
CSC Subpopulations Derived from Patient
Tumors
(A) Left: Excised subcutaneous tumors developed
from Matrigel-resuspended CD133+CD26+ cells of
a representative tumor (patient no. S3). Right:
Two-color flow cytometry of CD133+CD26+ cells
isolated from a primary tumor by MACS (98.13%
purity), showing no expression of CD45 and CK20.
(B) Tumorigenic potential of 13 105 CD26+CD44+,
CD26+CD44, CD26CD44+, and CD26CD44
cells within CD133+ and CD133 cell populations,
respectively, as well as unsorted tumor cells
derived from five primary tumors (patient no. S3,
S3M, P10, P18, and M8; flow cytometry analyses
of P10, S3, and S3M were shown in Figures
1A–1C, respectively). Xenografts were established
from subcutaneous injection of CD133+CD26+
cells from the five tumors, and the different cell
populations were isolated from the established
xenografts. Each group of mice (n = 4) was then
injected with the different subpopulations from
each of the five tumors. Data represent the
mean ± SD of tumor volume at different time points
of different groups.
(C) Tumor volumes of successive passages of
xenografts grown from CD133+CD26+ cells,
CD133+CD26CD44+ cells, and CD133+CD26
CD44 cells, respectively, isolated from a repre-
sentative human tumor (patient no. P1) at day 42
postinjection. The secondary xenograft was
generated from injection of 1 3 103 cells of the
respective populations isolated from xenografts
of the preceding passage into four animals in
each group. Data represent the mean ± SD of
tumor volume.
(D) H&E staining of xenograft passages shows well-
to moderately-differentiated adenocarcinomas
that are histologically similar to the parental tumor
(magnification 203, insets show sections of 403).
See also Table S3.
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EMT (Peinado et al., 2004). We therefore evaluated the expres-
sion of EMT regulatory proteins including E-cadherin, N-cad-
herin, E-cadherin repressor slug, twist, fibronectin, and vimentin
in CD26+ versus CD26 cells by western blot analysis. E-cad-
herin expression was downregulated in lysates of CD26+ cells
compared with CD26 cells. In addition, concomitant upregula-
tion of N-cadherin, the E-cadherin repressor slug, as well as
other EMT markers such as twist, fibronectin, and vimentin
was observed (Figure 5A). These findings suggest that EMT-
like attributes contribute to the invasive phenotype and meta-
static capacity of the CD26+ CSC subset.
To further demonstrate the functional role of CD26 in CD26+
CSCs, we downregulated CD26 expression by RNA interference
(Figure 5B). Transient transfection of CD26 siRNA decreased
migratory and invasive capacities of the CD26+ CSCs (Figure 5C),
as well as adhesion to fibronectin and type I collagen (Figure 5D).
Association between CD26 and integrin b1 is involved in cell
adhesion to both fibronectin and type I collagen (Sato et al.,
2005). Blockade of integrin signaling by anti-integrin antibody
inhibited adhesion of CD26+ CSCs to both fibronectin and
collagen (Figure 5E). Immunoblotting revealed that suppressionof CD26 decreased phosphorylation of integrin b1 at residue
Ser785, which is mandatory for the function of integrin b1 as an
adhesion molecule (Figure 5E; Mulrooney et al., 2001). Further-
more, suppression of CD26 in CD26+ cells led to concomitant
downregulation of EMT markers and upregulation of E-cadherin
(Figure 5F). Overall, these findings suggest that CD26 plays
a functional role in the invasive capacity of CD26+ CSCs.
Enhanced Liver Metastasis by Human
Intestinal Fibroblast
We further observed that coinjection of human intestinal fibro-
blast (HIF) isolated from normal human colon significantly
improved the development of metastasis. HIFs were coinjected
with the different cell subpopulations subcutaneously into
SCID mice. Tumor growth of CD133+CD26+CD44+ and CD133+
CD26+ cells was not enhanced. Moreover, tumor formation was
not apparent when HIFs were coinjected with CD133CD26
CD44 cells derived from the same tumor, demonstrating that
HIF was not tumorigenic in nature (Figure 5G). Next, we per-
formed orthotopic implantation of these CSCs in the presence
or absence of HIF. HIFs were injected into mice 2 days before
orthotopic implantation of CD133+CD26+ cells. In five of sixCell Stem Cell 6, 603–615, June 4, 2010 ª2010 Elsevier Inc. 607
Figure 3. Tumorigenic Capacity of Spheres Derived from CD26+ Cells
(A) Formation of spheres from CD133+CD26+ cells isolated from the primary and metastatic tumors, respectively, of a representative case of colorectal cancer
with synchronous liver metastasis (patient S4), and CD133+CD26CD44+ cells isolated from the primary and metastatic tumors of the same patient (week 4).
CD133CD26CD44 cells isolated from the same tumors did not form spheres under the same conditions (right panels).
(B) Immunofluorescence staining of CD133+CD26+ colonic spheres isolated from a representative tumor (patient S4). Spheres were stained with CD26-FITC (left)
and CD133-PE (middle), followed by merging of the two images (right).
(C) Dissociated spheres derived from CD133+CD26+, CD133+CD26CD44+, and CD133+CD26CD44 cells efficiently formed subspheres (secondary spheres)
in serial passages. Subsphere formation efficiency is the percentage of cells present (dissociated) in a single sphere that can form secondary spheres in each
passage. Each bar represents sphere formation from five patients (patients M1, M3, P2, P3, and P6) in triplicates counted at day 20 after plating.
(D) H&E staining of tumors grown by orthotopic injection of dissociated cells of spheres grown from CD133+CD26+ cells isolated from primary or metastatic
tumors, and CD133+CD26CD44+ cells isolated from the primary tumor (magnification 203, insets show sections of 403).
(E) Tumor formation from subcutaneous injection of 1 3 104 dissociated CD133+CD26+, CD133+CD26CD44+, and CD133+CD26CD44 cells from spheres of
a representative case (patient M1). An illustrative H&E stainingof tumorxenograft from CD133+CD26+ cells is shown (magnification203, insetsshowsections of403).
See also Table S4.
Cell Stem Cell
CD26+ Cancer Stem Cells in Colorectal Cancercases, tumor incidence in the colon was 100%, and all mice
developed liver metastasis. In the remaining case, although
orthotopic tumorigenicity was only apparent in three of four
mice, all three mice developed liver metastasis (Table S5). To
show that this observation was not a result of tumor sample vari-
ations, we performed the experiments with and without injection
of HIF, respectively, in two patient tumor samples with sufficient608 Cell Stem Cell 6, 603–615, June 4, 2010 ª2010 Elsevier Inc.cells isolated, which showed increased metastatic capacity with
preinjection of HIF (Figure 5G).
Chemoresistance of CD26+ CSCs
To investigate whether the CD26+ CSC subpopulations had
enhanced chemoresistance, dissociated tumor cells were
exposed to 5-fluorouracil (5-FU) or oxaliplatin in vitro and
Figure 4. Development of Metastasis from CD133+CD26+ Cells
(A) Orthotopic implantation of CD133+CD26+ cells from a primary tumor with synchronous liver metastasis (patient S2) in SCID mice led to primary tumor devel-
opment at the site of injection (left) and metastasis in the liver (right).
(B) H&E staining of the patient’s tumor and primary and secondary xenografts from a colorectal liver metastasis (patient M12) showing similar histology (magni-
fication 203, insets show sections of 403).
(C) Left: Metastases to the colon from orthotopic implantation of CD133+CD26+ cells from a primary colorectal cancer (patient 9). Right: Liver metastasis devel-
oped from CD133+CD26+ cells isolated from a primary colorectal cancer (patient 21).
(D) Top: Flow cytometry showing CD133+CD26+CD44+ cells in the portal vein blood from a mice at week 6 after orthotopic implantation of CD133+CD26+CD44+
cells isolated from a patient tumor. CD45 cells were gated for further analysis of CD133+, CD26+, and CD44+ expression. Bottom: Liver metastasis developed
from intraportal vein injection of CD133+CD26+CD44+ cells (week 9).
(E) Invasive and migratory capacities of CD133+CD26+ and CD133+CD26CD44+ tumor cells in Boyden chamber assay (left) and transwell migration assay (right).
Bars represent the mean ± SD of invaded/migrated cells isolated from established tumors of five different animals for each of the patient sample shown.
(F) Adhesive capacity of different cell populations to the ECM. Percent adhesion is calculated as the number of adhesive cells/adhesive cells+nonadhesive cells.
Data are expressed as the percent of adhesive cells determined over three fields per assay and expressed as an average of triplicate determinations.
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Figure 5. Functional Effects of CD26 Downregulation in CD26+ CSCs
(A) Immunoblotting of EMT proteins from lysates of CSCs isolated from primary or metastatic tumors of three different patients. CD133+CD26+ CSCs showed
significantly dysregulated EMT proteins compared with CD133+CD26CD44+ CSCs. Graph represents band density ratio of the respective protein to actin
(n = 3 for each protein).
(B) Depletion of CD26 expression by transient transfection of siCD26 oligo. Analysis of mRNA expression by RT-PCR (left) and protein expression by flow
cytometry (right) at 48 hr posttransfection.
(C) Invasive capacity of CD26+ cells transfected with nonsense control oligo (NS) or siCD26 oligo. Data represent the mean numbers of invaded cells per well and
performed in triplicates.
(D) CD26+ cells isolated from a primary colorectal tumor transiently transfected with CD 26 siRNA showed decreased adhesion to fibronectin, type I collagen, or
laminin. Percent adhesion is calculated as the number of adhesive cells/adhesive cells+nonadhesive cells. Data represent the mean of three different tumors (two
primary colorectal and one liver metastasis tumors).
Cell Stem Cell
CD26+ Cancer Stem Cells in Colorectal Cancer
610 Cell Stem Cell 6, 603–615, June 4, 2010 ª2010 Elsevier Inc.
Cell Stem Cell
CD26+ Cancer Stem Cells in Colorectal Canceranalyzed for CD133+CD26CD44+ or CD133+CD26+ CSC sub-
sets. Treatment with 5-FU decreased cell viability and enhanced
apoptosis, but led to enrichment of the CD133+CD26+ CSC
subpopulation (Figures 6A and 6B). On day 15 posttreatment,
about 80% of the cultivated cells were CD133+CD26+ (Fig-
ure 6B, lower panel). To investigate the in vivo relevance of
these findings, SCID mice bearing subcutaneous tumors estab-
lished from CD133+CD26+ CSCs received 5-FU, oxaliplatin, or
saline treatment. Treatment with either drug caused significant
tumor shrinkage compared with the control group (p < 0.001),
although substantial enrichment of the CD133+CD26+ CSC
subset was observed (Figures 6C and 6D). At 8 weeks posttreat-
ment, 80% or more of viable cancer cells in the tumors treated
by chemotherapy were CD133+CD26+, and the tumors started
to regrow after 8 weeks. These data suggested that chemother-
apeutic treatments that fail to eliminate CSCs may enrich the
metastatic CSC subpopulations.
DISCUSSION
The concept that onlyCSCs in a cancer are responsible for cancer
cell self-renewal and tumor growth is quite well established;
however, the role of CSCs in cancer metastasis remains unclear.
Hermann et al. showed that a CXCR4+ subpopulation within
CD133+ CSCs isolated from a metastatic pancreatic cell line
was responsible for the metastatic phenotype of the cell line,
and that in human pancreatic cancer the presence of CXCR4+
cells was associated with higher frequency of lymph node metas-
tasis (Hermann et al., 2007). However, the study did not show that
CXCR4+ CSCs isolated from human pancreatic cancer were en-
dowed with metastatic potential. We have identified a subpopu-
lation of CSCs from human tumors that are capable of forming
metastasis in an orthotopic animal model. Not only did we isolate
the subpopulation CD26+ CSCs from metastatic colorectal
tumors in the liver, but we also demonstrated that CD26+ CSCs
isolated from primary tumors were equally capable of forming
metastasis in our orthotopic model. Furthermore, the presence
of CD26+ CSCs in the primary tumor was predictive of develop-
ment of metastasis on clinical follow-up.
The majority of tumor-initiating cells isolated from both the
primary tumors and liver metastases were CD133+. This corrob-
orates with findings of many other studies of CSCs in colorectal
cancer (Dallas et al., 2009; Ferrand et al., 2009; Haraguchi
et al., 2008; O’Brien et al., 2007; Ricci-Vitiani et al., 2007). Among
the panel of CSC markers screened, only CD133 and CD44 were
differentially expressed in colorectal cancer compared with
their normal counterpart. CD26 was the only marker differentially
expressed in metastatic colorectal cancers compared with the
primary tumors. By analyzing CD44 and CD26 in the CD133+ cells(E) CD26+ cells preincubated with blocking antibodies against integrin b1 (4B4),
collagen. Data represent the mean of three different tumors (two primary colorec
integrin b1 at Ser785 was observed in CD26 siRNA, but not their corresponding
(F) Immunoblotting of EMT proteins from lysates of CD26+ cells transfected with
a colorectal cancer patient with liver metastasis.
(G) Tumor formation efficiency of CD133+CD26+CD44+, CD133+CD26+, and CD1
P2, and P5) in the presence/absence of HIF. Data represent the means of the thre
derived from a patient (S2) with (right) and without (left) preinjection of HIF.
See also Table S5.isolated from primary colorectal cancers and liver metastases,
we observed a significant association of the presence of CD26+
cells and liver metastasis. All synchronous and metachronous
liver metastases harbored CD26+ cells, whereas only 8 of 27
primary colorectal cancers without metastasis on presentation
harbored CD26+ cells. This suggests that CD26+ cells may be
a marker of distant metastasis in colorectal cancer. Furthermore,
among the 8 patients with primary colorectal cancer harboring
CD26+ cells, 5 developed liver metastasis during follow-up. The
other 3 patients had relatively short follow-up and it is possible
that liver metastasis may also develop in the future. In contrast,
none of the 19 patients without CD26+ cells developed distant
metastasis during follow-up.
The CSC properties of self-renewal and tumorigenicity of the
CD133+ cells were confirmed by serial passage in a xenograft
mice model. Coexpression of CD44 and CD133 seems to
enhance CSC tumorigenicity. This finding is in line with the signif-
icance of CD44+ CSCs in tumorigenicity of colorectal cancer and
other cancers (Al-Hajj et al., 2003). Our data support the concept
that tumors are generated and maintained by a subset of undif-
ferentiated cells with the ability to self-renew and regrow into the
bulk tumor population (Clarke et al., 2006; Dick, 2005; O’Brien
et al., 2007; Ricci-Vitiani et al., 2007; Singh et al., 2004).
The unique and most important finding of this study is the
capacity of CD26+ cells to form liver metastasis when injected
into the cecum of mice irrespective of CD133 or CD44 expres-
sion. However, coexpression of CD133 and CD44 did increase
the tumorigenic capacity of CD26+ cells. In contrast, CD26 cells
were not capable of forming liver metastasis, irrespective of
whether CD133 or CD44 was positive or negative. This is in line
with the clinical finding of association of CD26+ cells with liver
metastasis. Furthermore, CD26+ cells isolated from two primary
colorectal cancers without metastasis at the time of presentation
were also capable of initiating metastasis in the orthotopic mice
model, and both patients subsequently developed metastasis
during follow-up. Taken together, the clinical data and in vivo
studies suggested that CD26 is an important marker of a subset
of CSCs capable of forming metastasis in colorectal cancer. In
contrast, CD133 or CD44 was not associated with distant metas-
tasis but they appear to be markers of tumorigenicity. A caveat
noteworthy is that the tumorigenicity of the different cell popula-
tions might be different with the use of more immunologically
permissive mouse models, such as NOG mice, which has
recently been proposed to be a better xenograft model for CSC
studies (Quintana et al., 2008).
Our findings have significant clinical implication, because
examination for CD26+ cells in the primary colorectal cancer
may predict the development of distant metastasis. This may
facilitate patient selection for adjuvant chemotherapy to reducebut not isotype control IgG, showed decreased adhesion to fibronectin and
tal and one liver metastasis tumors). Decreased expression of phosphorylated
nonsense control (NS) transfectants.
nonsense control oligo (NS) or siCD26 oligo. CD26+ cells were isolated from
33CD26CD44 cells derived from three primary patient tumors (patients P1,
e patients for each subpopulation. Metastatic capacity of CD133+CD26+ cells
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Figure 6. Enrichment of CD133+CD26+ Cells by Chemotherapeutic Treatments
(A) Treatment of tumor cells with 5-FU in vitro decreased cell viability as shown by MTT assay. Data represent mean ± SD of tumor cells isolated from six different
patients in triplicates.
(B) Decreased cell viability was accompanied with enhanced apoptosis (upper panel) and enrichment of the CSC-positive subpopulation (lower panel).
(C) Treatment of tumor cells with 5-FU in vivo led to tumor shrinkage (left) markedly enriched the CD133+CD26+ subpopulation (right). Tumors from the control
group (saline) exceeded the maximum allowable sizes approved by Animal Ethics Committee and therefore were sacrificed beyond day 56.
(D) Treatment of tumor cells with oxaliplatin in vivo led to inhibition of tumor growth (left), but enrichment of the CD133+CD26+ subpopulation (right). Each point in
the tumor growth curve represents the mean ± SD of five animals. Each treatment group consisted of 30 animals, and three animals were sacrificed at each of the
indicated time points for analysis of the CD133+CD26+ subpopulation. Each bar in the right panel represents the mean percentage ± SD of viable cells from the
three excised tumors at the respective time point after treatment with oxaliplatin. Propidium iodine staining was performed to exclude dead cells from the disso-
ciated tumor by flow cytometry. Tumors from the control group (saline) exceeded the maximum allowable sizes approved by Animal Ethics Committee and there-
fore were sacrificed beyond day 42.
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CD26+ Cancer Stem Cells in Colorectal Cancerchance of recurrence after resection of primary colorectal
cancer. We have isolated CD26+ CSCs from peripheral blood
of patients with colorectal cancer (unpublished data), and612 Cell Stem Cell 6, 603–615, June 4, 2010 ª2010 Elsevier Inc.a further study is being conducted to evaluate its prognostic
value, which may provide a less invasive way of evaluating meta-
static CSCs.
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CD26+ Cancer Stem Cells in Colorectal CancerPrevious studies on CD26 have yielded various results in
different cancers. Preclinical studies showed that increased
CD26 inhibited metastasis in ovarian cancer (Kajiyama et al.,
2003), while suppression of CD26 promoted metastasis in pros-
tate cancer (Sun et al., 2008). On the other hand, inhibition of
CD26 in renal cell carcinoma decreased tumor growth and
reduced binding of the cancer cells to fibronectin and collagen
(Inamoto et al., 2006). Moreover, clinical studies in thyroid cancer
and gastrointestinal stromal tumors suggested that CD26
expression was associated with distant metastasis or recurrence
after resection (Hirai et al., 1999; Yamaguchi et al., 2008). The
pleiotrophic effects of CD26 may account for its varied roles in
different cancers (Havre et al., 2008). In colorectal cancer, signif-
icantly higher levels of circulating CD26 have been observed in
patients with metastatic disease (de la Haba-Rodrı´guez et al.,
2002). We showed that downregulation of CD26 reduced migra-
tion and invasion capacities of CD26+ cells and their binding to
fibronectin and collagen, which appeared to be mediated at least
in part through dephosphorylation of integrin b1. Furthermore,
suppression of CD26 decreased expression of EMT markers.
These data suggest that CD26 plays a functional role in the
invasive capacity of the CD26+ CSCs.
The detection of circulating CD26+ cells in the portal vein of
mice after cecal wall injection demonstrate that CD26+ cells
were capable of invasion through ECM and intravasation into
the circulation. Furthermore, metastatic growth in the liver after
intraportal vein injection of CD26+ cells suggests that CD26+
cells are capable of initiating growth of metastasis in distant
organs. These data further support metastatic capacity of CD26+
CSCs.
The increased incidence of metastatic tumors derived from
CSCs after preinjection of fibroblasts into the colon is an
interesting finding that suggests a possible role of microenviron-
ment in growth and expansion of CSCs. A plethora of scientific
data suggest that cell-to-cell interaction, cell-to-tissue matrix
contact, and the presence of certain signaling molecules within
the stem cell niche regulate stem cell homeostasis (Wei et al.,
2008; Weigelt and Bissell, 2008). A recent study suggests that
type 1 collagen, which is a major component of extracellular
matrix synthesized by fibroblasts, promotes the expression
CD133 in human colorectal cancer cells and enhances EMT
through downregulation of E-cadherin (Kirkland, 2009) Hence,
HIF may enhance the tumorigenic and metastatic capacity of
CSCs. However, the increased metastasis formation observed
with HIF coinjection may also be related to other phenomena,
such as enhanced angiogenesis or tumor-stromal interaction.
The mechanism by which HIF enhances metastasis remains to
be elucidated.
New regimens of systemic chemotherapy for colorectal
cancer have improved tumor response in recent years. However,
development of new metastases is very frequent. It has been
observed that even after apparently complete radiological
response to chemotherapy for liver metastasis from colorectal
cancer, in situ tumor recurrence occurred in >80% of patients
(Benoist et al., 2006). As demonstrated in our in vitro and
in vivo studies, this may be due to failure of chemotherapy in
eradicating CSCs. Chemotherapy may enhance the develop-
ment of further metastasis by enriching the CD26+ CSCs
subpopulation. Monoclonal antibody against CD26 has beenshown to inhibit growth and invasiveness of human renal
cell carcinoma, underscoring the potential of targeting CD26
(Inamoto et al., 2006). Further molecular characterization of the
CD26+ subpopulation is crucial for the development of new ther-
apeutic strategies targeting these CSCs.
In conclusion, our results suggest the existence of different
subsets of cancer cells with stem cell properties in tumor devel-
opment and progression: stationary CSCs that are tumorigenic
and responsible for growth of the primary tumors, and another
subset of CSCs endowed with metastatic capacity. Further
examination of this later population of CSCs will provide impor-
tant clues on malignant progression in colorectal cancer.
EXPERIMENTAL PROCEDURES
Sample Collection
Fresh tumor specimens were obtained with informed consent from patients
who underwent surgical resection of primary colorectal cancer and/or liver
metastasis at the Department of Surgery, Queen Mary Hospital, The University
of Hong Kong. The study was approved by Institutional Review Board. Histo-
logical assessment was performed by two experienced pathologists. The
World Health Organization standard grading system with four categories
(well differentiated, moderately differentiated, poorly differentiated, undiffer-
entiated) was used (Stanley and Lauri, 2000).
Isolation and Characterization of CSCs
Fresh tumor specimens were immediately minced on ice, suspended in
DMEM/F12 medium (Invitrogen, Carlsbad, CA), and dissociated with collage-
nase (Invitrogen) and hyaluronidase (Calbiochem, La Jolla, CA). Enzymatically
disaggregated suspensions were filtered and washed three times with PBS.
Red blood cells were removed by Histopaque-1077 (Sigma, St. Louis, MO).
The resulting single tumor cells were placed under stem cell conditions in
serum-free DMEM/F12 supplemented with human recombinant EGF (Invitro-
gen) and basic FGF (Invitrogen) and cultured on Ultra Low Attachment plates
(Corning Inc., Corning, NY) (Ponti et al., 2005).
Single-cell suspensions in stem cell medium (diluted as 10,000 to 1 cells/
well) were analyzed for tumor sphere formation, and numbers in each well
were quantified after 14 days. Tumor spheres were then disaggregated and
reseeded to evaluate self-renewal by formation of secondary tumor spheres.
Isolation was performed by magnetic-activated cell sorting (MACS) or fluo-
rescent-activated cell sorting (FACS). Nine subpopulations with different
expression of CD133, CD26, and CD44 were involved in the study: CD133+
CD26+CD44+, CD133+CD26+CD44, CD133+CD26CD44+, CD133+CD44
CD26, CD133+CD26+, CD133CD26+CD44+, CD133CD26+CD44, CD133
CD26CD44+, and CD133CD44CD26. Details of MACS and FACS of
different cell populations are provided in the Supplemental Experimental
Procedures.
In Vitro Migration and Invasion Assays
Migration and invasion of different cell populations were assessed with
transwell migration and Boyden chamber assays, respectively, as detailed in
Supplemental Experimental Procedures.
Depletion of Endogenous CD26 Expression
To deplete endogenous CD26, small interfering RNA (siRNA) oligo-targeting
CD26 cDNA (accession number NM_001935) was used: sense: AAAGAUUC
CUUCCUCCUGGCAUUCC, antisense: GGAAUGCCAGGAGGAAGGAAUCU
UU (Invitrogen Life Technologies, Carlsbad, CA), and nonsense scrambled
oligos (Stealth RNAi siRNA Negative Control, Invitrogen) was used as control.
Cells were transfected with 40 nM siRNA with Lipofectamine RNAiMAX
(Invitrogen) according to the manufacturer’s instructions and analyzed
between 48 to 72 hr posttransfection.
Preparation of Human Intestinal Fibroblasts
Human intestinal fibroblasts (HIF) were obtained from the adherent cell fraction
of overnight cultures from dissociated cells isolated from surgical tissueCell Stem Cell 6, 603–615, June 4, 2010 ª2010 Elsevier Inc. 613
Cell Stem Cell
CD26+ Cancer Stem Cells in Colorectal Cancerspecimens (macroscopically normal tissue) with a four-step enzymatic disper-
sion method as described previously (Bischoff et al., 1997). HIF (13 105) were
injected to the cecum of mice 2 days prior to orthotopic implantation of CD26+
cells isolated from patient tumors. Details of characterization of HIF are
provided in the Supplemental Experimental Procedures.
Chemoresistance of CD26+CSCs
To investigate whether the CD26+ CSC subpopulations from colorectal cancer
patients had enhanced chemoresistance, dissociated tumor cells were
exposed to 5-fluorouracil (5-FU) or oxaliplatin in vitro and analyzed for the
presence of CD133+CD26CD44+ or CD133+CD26+ CSC subsets.
Animal Studies
Animal study was approved by the Committee on the Use of Live Animals for
Teaching and Research of The University of Hong Kong. Severe combined
immune deficiency (SCID) mice were used for in vivo studies. To generate
subcutaneous tumors, suspensions of single cells with >90% viability were
subcutaneously injected into the flank of mice and tumor size was measured
every 3 days. For orthotopic implantation of tumor cells, mice were anesthe-
tized and the cecum was exteriorized by laparotomy. Cells (1 3 103/tumor)
suspended in 25 ml of DMEM F-12 medium and 25 ml Matrigel were slowly
injected with a 31-gauge needle to about 5 mm into the cecal wall. The incision
was then closed, and saline was injected s.c. on the flank to help maintain peri-
operative intravascular volume after the laparotomy. Animals were maintained
until death resulting from the neoplastic process or the end of the experiment
(180 days). For intraportal vein injection, a small incision in the abdomen was
made and 5 3 103 cells were slowly injected via a 28-gauge needle into the
portal vein.
For in vivo chemotherapeutic treatments, mice were randomly assigned to
a treatment group (oxaliplatin, 5-FU, or saline) at week 4 after subcutaneous
injection of CD133+CD26+ tumor cells (13 105). Mice received intraperitoneal
injections of 5-FU three times weekly for 28 days at 10, 20, or 30 mg/kg; oxa-
liplatin twice weekly for 28 days at 10 or 20 mg/kg; or saline. Each treatment
group consisted of 5 mice.
Statistical Analysis
Continuous variables are expressed as mean ± SD. Treatment groups were
compared with the independent or paired sample t test where appropriate.
In case of nonnormal distribution, the Mann-Whitney U test was used.
Comparison of nominal variables were performed via Chi-square test (or
Fisher’s exact test where appropriate). p values < 0.05 were considered statis-
tically significant. All analyses were performed with the SPSS 11.5 statistics
software (SPSS Inc., Chicago, IL).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and five tables and can be found with this article online at doi:10.1016/
j.stem.2010.04.001.
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